Literature DB >> 22258248

Mutation of the f-protein cleavage site of avian paramyxovirus type 7 results in furin cleavage, fusion promotion, and increased replication in vitro but not increased replication, tissue tropism, or virulence in chickens.

Sa Xiao1, Sunil K Khattar, Madhuri Subbiah, Peter L Collins, Siba K Samal.   

Abstract

We constructed a reverse genetics system for avian paramyxovirus serotype 7 (APMV-7) to investigate the role of the fusion F glycoprotein in tissue tropism and virulence. The AMPV-7 F protein has a single basic residue arginine (R) at position -1 in the F cleavage site sequence and also is unusual in having alanine at position +2 (LPSSR↓FA) (underlining indicates the basic amino acids at the F protein cleavage site, and the arrow indicates the site of cleavage.). APMV-7 does not form syncytia or plaques in cell culture, but its replication in vitro does not depend on, and is not increased by, added protease. Two mutants were successfully recovered in which the cleavage site was modified to mimic sites that are found in virulent Newcastle disease virus isolates and to contain 4 or 5 basic residues as well as isoleucine in the +2 position: (RRQKR↓FI) or (RRKKR↓FI), named Fcs-4B or Fcs-5B, respectively. In cell culture, one of the mutants, Fcs-5B, formed protease-independent syncytia and grew to 10-fold-higher titers compared to the parent and Fcs-4B viruses. This indicated the importance of the single additional basic residue (K) at position -3. Syncytium formation and virus yield of the Fcs-5B virus was impaired by the furin inhibitor decanoyl-RVKR-CMK, whereas parental APMV-7 was not affected. APMV-7 is avirulent in chickens and is limited in tropism to the upper respiratory tract of 1-day-old and 2-week-old chickens, and these characteristics were unchanged for the two mutant viruses. Thus, the acquisition of furin cleavability by APMV-7 resulted in syncytium formation and increased virus yield in vitro but did not alter virus yield, tropism, or virulence in chickens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258248      PMCID: PMC3302521          DOI: 10.1128/JVI.06765-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation.

Authors:  S Krishnamurthy; Z Huang; S K Samal
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

2.  Complete genome sequences of avian paramyxovirus serotype 6 prototype strain Hong Kong and a recent novel strain from Italy: evidence for the existence of subgroups within the serotype.

Authors:  Sa Xiao; Madhuri Subbiah; Sachin Kumar; Roberta De Nardi; Calogero Terregino; Peter L Collins; Siba K Samal
Journal:  Virus Res       Date:  2010-03-04       Impact factor: 3.303

3.  Recombinant Newcastle disease virus as a vaccine vector.

Authors:  T Nakaya; J Cros; M S Park; Y Nakaya; H Zheng; A Sagrera; E Villar; A García-Sastre; P Palese
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Generation of recombinant lentogenic Newcastle disease virus from cDNA.

Authors:  Angela Römer-Oberdörfer; Egbert Mundt; Teshome Mebatsion; Ursula J Buchholz; Thomas C Mettenleiter
Journal:  J Gen Virol       Date:  1999-11       Impact factor: 3.891

5.  Mutations in the fusion protein cleavage site of avian paramyxovirus serotype 2 increase cleavability and syncytium formation but do not increase viral virulence in chickens.

Authors:  Madhuri Subbiah; Sunil K Khattar; Peter L Collins; Siba K Samal
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

6.  Evidence for a new avian paramyxovirus serotype 10 detected in rockhopper penguins from the Falkland Islands.

Authors:  Patti J Miller; Claudio L Afonso; Erica Spackman; Melissa A Scott; Janice C Pedersen; Dennis A Senne; Justin D Brown; Chad M Fuller; Marcela M Uhart; William B Karesh; Ian H Brown; Dennis J Alexander; David E Swayne
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

7.  Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens.

Authors:  Sachin Kumar; Baibaswata Nayak; Peter L Collins; Siba K Samal
Journal:  J Virol       Date:  2011-04-27       Impact factor: 5.103

8.  Complete genome sequence of avian paramyxovirus (APMV) serotype 5 completes the analysis of nine APMV serotypes and reveals the longest APMV genome.

Authors:  Arthur S Samuel; Anandan Paldurai; Sachin Kumar; Peter L Collins; Siba K Samal
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

9.  Complete genome sequence of avian paramyxovirus type 7 (strain Tennessee) and comparison with other paramyxoviruses.

Authors:  Sa Xiao; Anandan Paldurai; Baibaswata Nayak; Madhuri Subbiah; Peter L Collins; Siba K Samal
Journal:  Virus Res       Date:  2009-06-18       Impact factor: 3.303

10.  Experimental infection of mice with avian paramyxovirus serotypes 1 to 9.

Authors:  Sunil K Khattar; Sachin Kumar; Sa Xiao; Peter L Collins; Siba K Samal
Journal:  PLoS One       Date:  2011-02-10       Impact factor: 3.240

View more
  11 in total

1.  Replication, neurotropism, and pathogenicity of avian paramyxovirus serotypes 1-9 in chickens and ducks.

Authors:  Shin-Hee Kim; Sa Xiao; Heather Shive; Peter L Collins; Siba K Samal
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

2.  Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models.

Authors:  Aryana Javaheri; Yonina Bykov; Ignacio Mena; Adolfo García-Sastre; Sara Cuadrado-Castano
Journal:  Cancer Res Commun       Date:  2022-07-07

3.  Characterization of novel avian paramyxovirus strain APMV/Shimane67 isolated from migratory wild geese in Japan.

Authors:  Eiji Yamamoto; Hiroshi Ito; Yukiko Tomioka; Toshihiro Ito
Journal:  J Vet Med Sci       Date:  2015-04-11       Impact factor: 1.267

Review 4.  A Review of Functional Motifs Utilized by Viruses.

Authors:  Haitham Sobhy
Journal:  Proteomes       Date:  2016-01-21

5.  Mutations in the fusion protein cleavage site of avian paramyxovirus serotype 4 confer increased replication and syncytium formation in vitro but not increased replication and pathogenicity in chickens and ducks.

Authors:  Shin-Hee Kim; Sa Xiao; Heather Shive; Peter L Collins; Siba K Samal
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

6.  Generation by reverse genetics of an effective, stable, live-attenuated newcastle disease virus vaccine based on a currently circulating, highly virulent Indonesian strain.

Authors:  Sa Xiao; Baibaswata Nayak; Arthur Samuel; Anandan Paldurai; Mallikarjuna Kanabagattebasavarajappa; Teguh Y Prajitno; Eny E Bharoto; Peter L Collins; Siba K Samal
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

7.  Evaluation of the replication, pathogenicity, and immunogenicity of avian paramyxovirus (APMV) serotypes 2, 3, 4, 5, 7, and 9 in rhesus macaques.

Authors:  Sunil K Khattar; Baibaswata Nayak; Shin-Hee Kim; Sa Xiao; Sweety Samal; Anandan Paldurai; Ursula J Buchholz; Peter L Collins; Siba K Samal
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

8.  Effect of fusion protein cleavage site sequence on generation of a genotype VII Newcastle disease virus vaccine.

Authors:  Vinoth K Manoharan; Berin P Varghese; Anandan Paldurai; Siba K Samal
Journal:  PLoS One       Date:  2018-05-14       Impact factor: 3.240

Review 9.  The Proteolytic Regulation of Virus Cell Entry by Furin and Other Proprotein Convertases.

Authors:  Gonzalo Izaguirre
Journal:  Viruses       Date:  2019-09-09       Impact factor: 5.048

Review 10.  Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.

Authors:  Amene Saghazadeh; Nima Rezaei
Journal:  Int Immunopharmacol       Date:  2020-05-08       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.